Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3162 | Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki | 0.38 |
| drug245 | Antibody testing Wiki | 0.38 |
| drug2400 | Pemziviptadil (PB1046) Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1828 | Low Dose (10 mg) Control Wiki | 0.38 |
| drug2182 | No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.. Wiki | 0.38 |
| drug3001 | Senicapoc Wiki | 0.38 |
| drug326 | Awake Prone Positioning Wiki | 0.38 |
| drug3394 | Tracheotomy Wiki | 0.38 |
| drug3165 | Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki | 0.38 |
| drug2144 | Nicotinamide riboside Wiki | 0.38 |
| drug3164 | Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation Wiki | 0.38 |
| drug299 | Association of diltiazem and niclosamide Wiki | 0.38 |
| drug3163 | Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection Wiki | 0.38 |
| drug3148 | Standard of care (SOC) Wiki | 0.22 |
| drug3299 | Telmisartan Wiki | 0.22 |
| drug3132 | Standard care Wiki | 0.13 |
| drug879 | Convalescent plasma Wiki | 0.08 |
| drug1472 | Hydroxychloroquine Wiki | 0.04 |
| drug2448 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000075902 | Clinical Deterioration NIH | 0.27 |
| D011654 | Pulmonary Edema NIH | 0.22 |
| D006333 | Heart Failure NIH | 0.13 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.08 |
| D013577 | Syndrome NIH | 0.07 |
| D000860 | Hypoxia NIH | 0.07 |
| D007249 | Inflammation NIH | 0.07 |
| D055371 | Acute Lung Injury NIH | 0.06 |
| D012141 | Respiratory Tract Infections NIH | 0.06 |
| D011014 | Pneumonia NIH | 0.04 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0010444 | Pulmonary insufficiency HPO | 1.00 |
| HP:0100598 | Pulmonary edema HPO | 0.22 |
| HP:0001635 | Congestive heart failure HPO | 0.13 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002088 | Abnormal lung morphology HPO | 0.08 |
| HP:0012418 | Hypoxemia HPO | 0.07 |
| HP:0011947 | Respiratory tract infection HPO | 0.06 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 7 clinical trials
The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.
Description: Estimated by Polymerase chain reaction (PCR)
Measure: The change of viral load in patients with SARS-COVID-19. Time: Upon patient inclusion in the study, after 96 hours and on the 10day;Description: Assessed through the entire patient participation in the study
Measure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS) Time: up to 10 daysDescription: The number of days a patient is hospitalized
Measure: Duration of hospitalization Time: up to 10 daysDescription: Early mortality from all causes will be estimated
Measure: The frequency of early mortality Time: up to 30 daysDescription: Late mortality from all causes will be estimated
Measure: The frequency of late mortality Time: up to 90 daysDescription: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.
Measure: Clinical status at the time of completion of participation in the study Time: an average of 10 daysProne positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ARDS) patients, with demonstrated reductions in mortality. Preliminary data suggest that awake proning in patients with COVID-19 treated with high-flow nasal oxygenation (HFNO) improves gas exchanges, and might be associated with a reduced need of mechanical ventilation, and reduced mortality. Further investigation in a formal randomized-controlled trial is need.
Description: Total time spent in prone position, as recorded by nursing or respiratory therapists
Measure: Time in prone position Time: Up to 28 days post randomizationDescription: Daily evolution of oxygenation
Measure: Oxygenation (SpO2/FiO2 ratio) Time: Until HFNC weaning, or up to 14 days after randomization, whichever is firstCritically ill covid-19 patients may require respiratory support including mechanical ventilation. After an initial period with an endotracheal tube, a tracheotomy is performed in order to reduce potential airway complications, reduce the need of sedation and facilitate the monitoring and recovery. The optimal timing of this surgical procedure is, however, still unknown. The aim of this randomized, controlled trial is to compare the outcome of early (within 7 days) vs late (after at least 10 days) tracheotomy in covid-19 patients. The need for mechanical ventilation, sedation, additional oxygen support, frequency of complications, duration at the ICU and mortality will be evaluated and compared.
Description: Number of days without mechanical ventilation
Measure: Mechanical ventilation Time: 28 daysDescription: Number of days at ICU
Measure: ICU stay Time: 28 daysDescription: Number of days with need of additional oxygen support
Measure: Oxygen support Time: 28 daysDescription: Number of days with the need of sedation
Measure: Sedation Time: 28 daysDescription: Various adverse events associated with the tracheotomy/tracheostomy
Measure: Adverse events Time: 28 daysDescription: Mortality
Measure: Mortality Time: 90 daysThis is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy
Measure: Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 daysRationale: The renin-angiotensin-aldosterone system (RAAS) dysregulation may play a central role in the pathophysiology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection associated acute lung injury (ALI) / acute respiratory distress syndrome (ARDS). In the RAAS, Angiotensin I (Ang I) is converted to angiotensin II (Ang II) by angiotensin converting enzyme (ACE). Ang II mediates vasoconstrictive, pro-inflammatory and pro-oxidative effects through agonism at Ang II type 1 receptor (AT1R). ACE2 converts Ang II to angiotensin 1-7 (Ang1-7), which finally binds to Mas receptor (MasR) and mediates many beneficial actions, including vasodilation and anti-inflammatory, anti-oxidant and antiapoptotic effects. ACE2, a homologue of ACE, is an integral cell membrane protein with a catalytic domain on the extracellular surface exposed to vasoactive peptides. SARS-CoV-2 penetrates the cell through ACE2, and the increase of this receptor (due to the use of ACE inhibitors or angiotensin receptor blockers [ARBs]) may facilitate SARS-CoV-2 infection, which might increase the risk of developing severe and fatal SARS-CoV-2 infection. However, through upregulation of ACE2, ACE inhibitors/ARBs can exert anti-inflammatory and antioxidative effects, which may be beneficial in preventing ALI and ARDS. Objective: To evaluate the effectiveness and safety of telmisartan in respiratory failure due to COVID-19. Study design: This is an open label, phase 2 clinical trial. Study population: Adult hospitalized SARS-CoV-2-infected patients (n=60). Intervention: The active-treatment arm will receive telmisartan 40 mg daily and the control arm will receive standard care. Treatment duration will be 14 days or up to hospital discharge <14 days or occurrence of the primary endpoint if <14 days. Main study endpoint: The primary study endpoint is the occurrence within 14 days of randomization of either: 1) Mechanical ventilation or 2) Death.
Description: Death is defined as all-cause mortality
Measure: Death Time: Within 30 daysDescription: Occurrence of mechanical ventilation
Measure: Mechanical ventilation Time: Within 14 daysDescription: Defined as a 50% decline in estimated glomerular filtration rate relative to baseline, or decrease of >30 ml/min/1.73m2 and to a value below 60 ml/min/1.73m2
Measure: Occurrence of acute kidney injury Time: Within 14 daysDescription: Incidence of episodes of blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic
Measure: Incidence of hypotension Time: Within 14 daysDescription: Outcome reported as the number of participants in each arm requiring the use of vasopressors for hypotension
Measure: Incidence of hypotension requiring vasopressors Time: Within 14 daysDescription: Outcome reported as the number of participants in each arm who experience sepsis, defined as the presence of at least 2 of the following clinical criteria together (qSOFA score): respiratory rate of 22/min or greater, altered mentation, or systolic blood pressure of 100 mm Hg or less
Measure: Incidence of Sepsis Time: Within 14 daysDescription: Hospital length of stay (days)
Measure: Hospital length of stay Time: Within 14 daysSARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19. The virus has subsequently spread throughout the world and was declared a pandemic by the World Health Organisation on 11th March 2020. As of April 1, 2020, there are 874.081 numbers of confirmed cases with 43.290 fatalities. There is no approved therapy for COVID-19 and the current standard of care is supportive treatment. Key markers implying a fatal outcome are acute respiratory distress syndrome (ARDS)-like disease with pronounced dyspnea, hypoxia and radiological changes in the lung. Senicapoc improves oxygenation and reduces fluid retention, inflammation, and bleeding in the lungs of mice with ARDS-like disease. In cells, there is an antiviral effect of senicapoc.
Description: The PaO2/FiO2 ratio will be calculated based on the arterial gas closest to the time-point of Day 3 after randomization
Measure: PaO2/FiO2 ratio Time: Day 3Description: Ventilator-free days will be defined as the number of days (or proportion of days) within the first 28 days after randomization where the patient is alive and not on invasive mechanical ventilation
Measure: Ventilator-free days Time: Day 28Description: Assessment of mortality is considered a core outcome for trials within acute respiratory failure
Measure: Mortality Time: Day 28Description: An infusion of a vasopressor will be defined as any continuous infusion of noradrenaline, dopamine, dobutamine, terlipressin, vasopressin, phenylephrine, and/or adrenaline
Measure: Vasopressor-free days Time: Day 28Description: The Sequential Organ Failure Assessment (SOFA)-score 1-4 will be used with 1 as best and 4 as worst score. The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. The sub scores as well as the overall SOFA score will be assessed. The calculation of the SOFA score will be based on available clinical and laboratory data. Laboratory and clinical data closest to the given time point will be used. If a given component (e.g. bilirubin) is not available, it will be assumed to be within normal ranges.
Measure: Sequential Organ Failure Assessment (SOFA)-score Time: Day 1, 2, 3, and 5Description: Renal replacement therapy includes dialysis (hemodialysis or peritoneal dialysis), hemofiltration, and hemodiafiltration.
Measure: Need for renal replacement therapy Time: Day 28Description: Health-related quality of life (EQ-5D-5L) in 5 dimensions and 5 levels (1-5) with 1 as worst and 5 as best level in each dimension. At day 28 EQ-5D-5L will be assessed via telephone communication with the patient or a surrogate. The telephone interview will be semi-structured and based on the EQ-5D-5L questionnaire. The interview will be conducted by a centrally-located and trained member of the research team according to detailed standard operating procedures. In case the patient is still in the hospital, this interview will be face-to-face.
Measure: Health-related quality of life (EQ-5D-5L) Time: Day 28Description: Quantification of viral load before and after treatment
Measure: Measurement of SARS-CoV2 load Time: Day 0 and 3One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary treatment. Primary outcome is number of days the patients need oxygen within 28 days from inclusion. Secondary outcome is number of days in hospital, number of days in respirator and mortality. Side effects of treatment is monitored.
Description: Number of days in need of oxygen within 28 days from inclusion
Measure: Number of days in need of oxygen Time: 28 daysDescription: number of days before discharge from hospital
Measure: Number of days before discharge from hospital Time: 3 monthsDescription: death of patient
Measure: Mortality within 3 months Time: 3 monthsDescription: number of days before need of assisted ventilation
Measure: Number of days before need of assisted ventilation Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports